Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study

Blood

Volumn 99, Issue 6, 2002, Pages 1928-1937

  Talpaz, Moshe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Silver, Richard T ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Druker, Brian J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Goldman, John M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Gambacorti Passerini, Carlo ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Guilhot, Francois ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Schiffer, Charles A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Fischer, Thomas ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Deininger, Michael W N ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Lennard, Anne L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Hochhaus, Andreas ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Ottmann, Oliver G ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Gratwohl, Alois ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Baccarani, Michele ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Stone, Richard ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Tura, Sante ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Mahon, Francois Xavier ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Fernandes Reese, Sofia ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Gathmann, Insa ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Capdeville, Renaud ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Kantarjian, Hagop M ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   Sawyers, Charles L ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t}   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e SAN GERARDO HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m GOETHE UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o UNIVERSITY HOSPITAL OF UDINE   (Italy)

^p DANA FARBER CANCER INSTITUTE   (United States)

^q UNIVERSITY OF BOLOGNA   (Italy)

^r UNIVERSITÉ DE BORDEAUX   (France)

^s NOVARTIS PHARMA AG   (Switzerland)

^t UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0037085785     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.1928     Document Type: Article

References (41)

1. Chronic myeloid leukemia
2. Chronic myelogenous leukemia: Biology and therapy
3. Characteristics of accelerated disease in chronic myelogenous leukemia
4. Chronic myelogenous leukemia: A concise up-date
5. Characteristics of the terminal phase of chronic granulocytic leukemia
6. Blastic phase of chronic myeloid leukemia (blVML): A proposal for standardization of diagnostic and response criteria
7. Allogeneic bone marrow transplantation for chronic myelogenous leukemia
8. Staging and prognosis in chronic myelogenous leukemia
9. Treatment of chronic myelogenous leukemia: Current status and investigational options
10. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
11. A minute chromosome in human chronic granulocytic leukemia
12. Acute leukemia in bcr/abl transgenic mice
13. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
14. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
15. Bcr/abl, the hallmark of chronic myelogenous leukemia in man, induces multiple hematopoietic neoplasms in mice
16. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemias: Developed for the American Society of Hematology
17. Chronic myelogenous leukemia
18. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubcin, high-dose cytarabine and granulocyte macrophage colony stimulating factor
19. Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse
20. Bone marrow transplantation for chronic myeloid leukemia: Long term results
21. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation
22. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia
23. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia
24. Related donor marrow transplant for chronic myeloid leukemia: Patient characteristics predictive of outcome
25. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
26. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
27. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemia cells and induces apoptosis
28. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
29. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia
30. Activity of an abl specific tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis and other Philadelphia chromosome positive acute leukemias
31. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
32. Treatment of advanced stages of Philadelphia chromosome positive chronic myelogenous leukemia with interferon-alpha and low dose cytarabine
33. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
34. Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies
35. Cancer research: Why some leukemia cells resist STI-571
36. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
37. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells
38. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanism of resistance
39. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
40. Clinical investigation of the PK/PD relationship for Glivec (STI571): A novel inhibitor of signal transduction